These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 796526)

  • 21. Effect of pyridinolcarbamate (PDC) on surface microvessels in man: preliminary findings.
    Rouen LR; Terry EN; Clauss RH; Redisch W
    Bibl Anat; 1975; 13():358-9. PubMed ID: 1231780
    [No Abstract]   [Full Text] [Related]  

  • 22. [Use of disaggregants in treating diabetic retinopathy].
    Saldan IR
    Oftalmol Zh; 1984; (7):395-8. PubMed ID: 6527859
    [No Abstract]   [Full Text] [Related]  

  • 23. [Thermal test of reactive hyperemia: a propos of an objective study of pyridinol carbamate].
    Lauliac M
    Phlebologie; 1978; 31(2):119-29. PubMed ID: 693585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Action of salicylic acid and pyridinolcarbamate on the platelet aggregation (author's transl)].
    Altman R; Rouvier J; Taboada S; Mosquera G
    Sangre (Barc); 1974; 19(4):385-98. PubMed ID: 4445961
    [No Abstract]   [Full Text] [Related]  

  • 25. [Rheographic normalization in prediabetic subjects treated with pyridinolcarbamate].
    Furitano G; Paterna S; Di Pasquale P
    Minerva Med; 1978 May; 69(24):1655-9. PubMed ID: 662168
    [No Abstract]   [Full Text] [Related]  

  • 26. [Activity of the kallikrein-kinin system in patients with ischemic heart disease treated with parmidine].
    Vygovskiĭ VP; Zaremba EF; Podil'chak EM; Dutka RIa; Gorgota OV
    Vrach Delo; 1985 Sep; (9):6-8. PubMed ID: 2416131
    [No Abstract]   [Full Text] [Related]  

  • 27. [Effect of Prodectin on various blood clotting factors].
    Czaplicki S; Ostrowska B; Sułek K
    Pol Tyg Lek; 1978 Sep; 33(39):1541-4. PubMed ID: 704456
    [No Abstract]   [Full Text] [Related]  

  • 28. [Effect of parmidine (pyridinolcarbamate) on thrombocyte aggregation, blood clotting and fibrinolysis].
    Mashkovskiĭ MD; Lakin KM; Ovnatanova MS; Shvarts GIa
    Biull Eksp Biol Med; 1976 Mar; 81(3):322-4. PubMed ID: 953280
    [No Abstract]   [Full Text] [Related]  

  • 29. [Experimental studies of parmidin (pyridinolcarbamate) effect on microvascular permeability of the lungs, skin and mesentery].
    Gorizontoba MP; Shvarts GIa
    Biull Eksp Biol Med; 1979 Sep; 88(9):272-5. PubMed ID: 519015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of prodectin in the treatment of cerebral arteriosclerosis and its complications.
    Abrányi I; Máté
    Ther Hung; 1976; 24(1):20-3. PubMed ID: 790631
    [No Abstract]   [Full Text] [Related]  

  • 31. The effect of pyridinolcarbamate after acute and chronic administration in patients with atherosclerosis obliterans.
    Roztocil K; Oliva J; Linhart J; Prerovský I; Modr Z
    Int J Clin Pharmacol Biopharm; 1977 Mar; 15(3):135-8. PubMed ID: 844932
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effect of complamin and prodectin on microcirculation and lipid metabolism in psoriasis patients].
    Rakhmatov AB; Bilash NV
    Vestn Dermatol Venerol; 1983 Apr; (4):15-8. PubMed ID: 6868813
    [No Abstract]   [Full Text] [Related]  

  • 33. [Critical study of the in vitro and in vivo effect of pyridinol carbamate on platelet adhesiveness and aggregation].
    Prost-Djovakovic RJ; Lecrubier C; Doumenc J; Samama M
    Therapie; 1975; 30(3):429-42. PubMed ID: 772874
    [No Abstract]   [Full Text] [Related]  

  • 34. [Hemostasis and microcirculation in diabetic angiopathy].
    Petrova TR; Vil'chinskaia MN
    Sov Med; 1984; (4):98-101. PubMed ID: 6740413
    [No Abstract]   [Full Text] [Related]  

  • 35. [Xanthinic derivatives in the treatment of intermittent claudication syndrome in diabetic patients].
    Gómez Reyes D; Rojas Hidalgo E
    Rev Clin Esp; 1986 Jul; 179(3):162. PubMed ID: 3764000
    [No Abstract]   [Full Text] [Related]  

  • 36. [Changes of the electrophoretic tracing of the serum glycoproteins in diabetic subjects treated with pyridinolcarbamate].
    Notarbartolo A; Rini GB; Di Fede G
    Boll Soc Ital Cardiol; 1973; 18(4):379-83. PubMed ID: 4807078
    [No Abstract]   [Full Text] [Related]  

  • 37. [Psychophysiological aspect of the therapeutic use of pyridinolcarbamate].
    Sidorenko GI; Borisova GS; Sidorenko ER; Polonetskii LZ; Gelis LG
    Kardiologiia; 1983 Mar; 23(3):66-71. PubMed ID: 6855067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The effect of antiaggregants on the course of diabetic microangiopathy].
    Bokarev IN; Velikov VK; Zelenchuk NM; Shubina OI; Saltykov BB; Frolova AI; Polunin GS; Pirogova EP; Nikol'skaia VV; Davydova NG
    Ter Arkh; 1993; 65(3):78-81. PubMed ID: 8059393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diabetic glomerulosclerosis in KK mice and its prevention by glyburide and pyridinolcarbamate.
    Camerini-Davalos RA; Reddi AS; Ehrenreich TH; Strugatz LH; Oppermann W
    Adv Exp Med Biol; 1979; 119():387-400. PubMed ID: 115232
    [No Abstract]   [Full Text] [Related]  

  • 40. Anti-proliferative effect of pyridinolcarbamate and of aspirin in the early stages of atherogenesis in swine.
    Kim DN; Lee KT; Schmee J; Thomas WA
    Atherosclerosis; 1983 Jul; 48(1):1-13. PubMed ID: 6882504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.